Given the increasing use of testosterone in the USA and elsewhere, [1] [2] [3] 4 provide a timely assessment of its potential benefits and risks. The authors are cautious about testosterone therapy as a potential treatment for low testosterone levels in older men (defined as men aged >65 years) because, apart from lingering concerns about prostate cancer, testosterone therapy raises hematocrit and lowers HDLcholesterol levels, 4 although this therapy can also improve exercise capa city among men with heart failure. 5 Spitzer et al. suggest large prospective randomized trials to establish the effects of testosterone therapy on cardiovascular health. Such trials may be the best way to determine the effects of testosterone on the leading cause of mortality and morbidity, where even a very small change in risk would have a large effect on population health. On the other hand, results of such prospective trials, similar to the Women's Health Initiative trial, 6 for example, can take a decade to obtain; however, use of testosterone is increasing rapidly now. [1] [2] [3] Consideration of all the evidence to date should guide policy in the interim.
No large trial has ever been implemented to assess the effect of testosterone on cardio vascular health. Meta-analysis of small trials might be more reliable than a large trial. 7 Spitzer et al. report a pooled odds ratio of about 1.8 (95% CI 0.8-4.2) for the effect of testosterone therapy on cardiovascular events in their Figure 3 We recently published an updated metaanalysis, which included 27 trials investigating the effects of testosterone therapy on 180 cardiovascular-related events among 2,994 mainly older men (average age 62 years).
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The pooled odds ratio for testosterone therapy on cardiovascular-related events was 1.54 (95% CI 1.09-2.18), with a higher event rate and odds ratio for trials not funded by the pharmaceutical industry.
Of course, existing on-going trials may show testosterone to be protective against cardiovascular disease and thereby reduce the estimate of harm; however, this hypo thesis would be against the run of evidence to date.
On the basis of the current evidence, any large prospective randomized trial to definitively establish the effects of testosterone on cardiovascular health should perhaps be of an agent that reduces testosterone, rather than administration of testosterone. Notably, one such agent, statins, 12 is already in widespread use to treat cardiovascular disease, but other suitable agents might also exist. Such trials could also assess whether any effects on cardiovascular disease are, at least in part, mediated by their effect on testosterone.
